All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: tni.ohw@sredrokoob). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: tni.ohw@snoissimrep).
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Significant progress is being made in the global scale-up of prevention of mother-to-child transmission of HIV (PMTCT), including in high burden and resource-limited settings. For the first time, the elimination of mother-to-child transmission of HIV (MTCT) is now considered a realistic public health goal and an important part of the campaign to achieve the millennium development goals.
In the light of the global effort, it is critically important to provide the best evidence-based interventions to reduce the risk of transmission from an HIV-infected mother to her newborn child, while at the same time promoting the health of both the mother and the child.
Since WHO issued revised guidelines in 2006, important new evidence has emerged on the use of antiretroviral (ARV) prophylaxis to prevent MTCT, including during breastfeeding, on the optimal time to initiate antiretroviral therapy (ART) in individuals who need treatment, and on safe feeding practices for HIV-exposed infants.
This evidence forms the basis for the new recommendations contained in these 2010 revised guidelines and summarized in preliminary form in the 2009 Rapid Advice: Use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants. The Rapid Advice gives a list of the key recommendations whereas the full guidelines document presents in detail the scientific evidence and rationale supporting these recommendations. The detailed guidelines document provides the necessary information for countries to adapt the WHO recommendations to their local settings.
The 2010 guidelines are developed to provide international standards, primarily for low- and middle-income settings, in support of the global scale-up of more effective interventions aimed at preventing MTCT in resource-limited settings. Once implemented, these recommendations could reduce the risk of MTCT to less than 5% (or even lower) in breastfeeding populations from a background risk of 35%, and to less than 2% in non-breastfeeding populations from a background risk of 25%, and will ensure increased maternal and child survival.
The 2010 revision of the WHO guidelines on PMTCT complies with the recently updated WHO guidelines development process, which requires systematic review of new evidence for key questions and recommendations, as well as a consideration of programme feasibility and the cost implications of potential new recommendations. WHO has simultaneously revised guidelines for adult ART as well as HIV and infant feeding. All three sets of guidelines were updated in a harmonized fashion.
Contents
- ACKNOWLEDGEMENTS
- ABBREVIATIONS AND ACRONYMS
- SUMMARY OF RECOMMENDATIONS
- I. INTRODUCTION AND OBJECTIVES
- II. DEVELOPMENT OF THE GUIDELINES AND GUIDING PRINCIPLES
- III. ANTIRETROVIRAL DRUGS FOR TREATING PREGNANT WOMEN FOR THEIR OWN HEALTH AND TO PREVENT HIV INFECTION IN THEIR INFANTS
- Key recommendations
- ART eligibility for pregnant women
- ART regimens for pregnant women eligible for treatment
- ART regimens for women of childbearing age receiving treatment for their own health
- Antiretroviral prophylaxis for infants born to women receiving ART
- Clinical and laboratory monitoring of pregnant women receiving ART for their own health and their infants
- IV. MATERNAL AND INFANT ARV PROPHYLAXIS TO PREVENT MTCT FOR HIV-INFECTED PREGNANT WOMEN WHO DO NOT NEED TREATMENT FOR THEIR OWN HEALTH
- Key recommendations
- ARV prophylaxis for women and their infants to reduce perinatal HIV transmission
- Maternal AZT plus infant ARV prophylaxis to prevent MTCT (option A)
- Maternal triple ARV prophylaxis to prevent MTCT (option B)
- Women diagnosed during labour or immediately postpartum
- Clinical and laboratory monitoring of pregnant women receiving ARV prophylaxis and their infants
- V. SPECIAL CONSIDERATIONS
- ARV regimens for women previously exposed to antiretroviral drugs
- Women who acquire primary infection during pregnancy or breastfeeding
- Women with anaemia
- Women with HIV-2 infection
- Women with active tuberculosis
- Women with hepatitis B or hepatitis C virus coinfection
- Pregnant women living with HIV who are injecting drug-users
- VI. SAFETY AND RISK OF RESISTANCE TO ANTIRETROVIRAL DRUGS IN PREGNANT WOMEN AND THEIR INFANTS
- VII. HEALTH SYSTEMS CONSIDERATIONS OF ARV-BASED INTERVENTIONS FOR WOMEN AND INFANTS
- ANNEXES
- REFERENCES
The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.
The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.
- NLM CatalogRelated NLM Catalog Entries
- Review HIV transmission through breastfeeding: problems and prevention.[Ann Trop Paediatr. 2003]Review HIV transmission through breastfeeding: problems and prevention.Ogundele MO, Coulter JB. Ann Trop Paediatr. 2003 Jun; 23(2):91-106.
- Review Prevention of Mother-to-Child Transmission of HIV and Syphilis.[Major Infectious Diseases. 2017]Review Prevention of Mother-to-Child Transmission of HIV and Syphilis.John-Stewart G, Peeling RW, Levin C, Garcia PJ, Mabey D, Kinuthia J. Major Infectious Diseases. 2017 Nov 3
- Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial.[Lancet Infect Dis. 2011]Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial.Kesho Bora Study Group, de Vincenzi I. Lancet Infect Dis. 2011 Mar; 11(3):171-80. Epub 2011 Jan 13.
- [Preventing the transmission of HIV-1 from mother to child in Africa in the year 2000].[Sante. 2000][Preventing the transmission of HIV-1 from mother to child in Africa in the year 2000].Castetbon K, Leroy V, Spira R, Dabis F. Sante. 2000 Mar-Apr; 10(2):103-13.
- Safety and effectiveness of antiretroviral drugs during pregnancy, delivery and breastfeeding for prevention of mother-to-child transmission of HIV-1: the Kesho Bora Multicentre Collaborative Study rationale, design, and implementation challenges.[Contemp Clin Trials. 2011]Safety and effectiveness of antiretroviral drugs during pregnancy, delivery and breastfeeding for prevention of mother-to-child transmission of HIV-1: the Kesho Bora Multicentre Collaborative Study rationale, design, and implementation challenges.Kesho Bora Study Group. Contemp Clin Trials. 2011 Jan; 32(1):74-85. Epub 2010 Sep 17.
- Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in...Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants: Recommendations for a Public Health Approach
- tgfb2 [Eleginops maclovinus]tgfb2 [Eleginops maclovinus]Gene ID:134862041Gene
Your browsing activity is empty.
Activity recording is turned off.
See more...